Participated · Series C · Jul 2026

Allotera Therapeutics (formerly Wugen) is advancing Soficabtagene Geleucel (Sofi-cel), a CD7-targeted allogeneic, off-the-shelf CAR-T cell therapy for T-cell malignancies. Sofi-cel is manufactured from healthy donor T cells in the United States and uses CRISPR/Cas9 to delete CD7 and TRAC to reduce fratricide and graft-versus-host disease risk. Sofi-cel is being evaluated in a global pivotal T-RRex clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (ClinicalTrials.gov identifier NCT06514794). The therapy has received multiple regulatory designations, including Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease in the U.S., and PRIME in the EU. The company says its approach aims to address biological and manufacturing barriers in T-cell CAR-T development and is using recent financing to support pivotal development, manufacturing scale-up, platform advancement, and team growth. Allotera is headquartered in St. Louis.

Participated · Series B · Mar 2026

Crossbow Therapeutics is developing a portfolio of T-Bolt™ T-cell engager (TCE) therapies built from T-cell receptor-mimetic antibodies that target peptide–HLA (pHLA) complexes on cancer cells. Its lead program, CBX-250, is a first-in-class TCE targeting a pHLA specific to myeloid cancer cells and is being evaluated in the ongoing CROSSCHECK-001 Phase 1 trial in relapsed and refractory myeloid malignancies. The company is advancing CBX-663, a TCE targeting a TERT-derived pHLA, toward IND submission and a planned Phase 1 start in Q3 2026 for multiple hematologic and solid tumors. Crossbow positions its T-Bolt™ platform as broadly adaptable to address intracellular cancer targets previously unreachable by antibodies. The company will present preclinical data for both programs at the AACR 2026 Annual Meeting and expects initial clinical data from CBX-250 around the end of 2026. The recent $77 million Series B is intended to fund completion of CBX-250’s Phase 1 and to accelerate initiation and development of additional T-Bolt™ programs.

Participated · Equity · Jun 2025

Enterome is a clinical-stage company developing first-in-class OncoMimics immunotherapies, led by lead candidate EO2463. EO2463 is an off-the-shelf immunotherapy combining four synthetic OncoMimics peptides that mimic B‑cell markers (CD20, CD22, CD37 and CD268/BAFF receptor) plus a helper peptide (UCP2) to target malignant B lymphocytes. The approach aims to provide broad target coverage to improve safety and maximize efficacy while reducing antigen-escape driven resistance. Enterome is expanding and finalizing its Phase 1/2 SIDNEY clinical trial and preparing EO2463 for a registrational program, including a planned pivotal Phase 3 for the “watch-and-wait” iNHL population. The company has held positive interactions with regulators (FDA Type C meeting and EMA Scientific Advice) that outline a clear path to marketing authorization in watch-and-wait iNHL. New and prior clinical data (including ASCO 2024 and upcoming ICML presentation) support EO2463’s activity as monotherapy and in combination and suggest biomarker-driven identification of likely responders. Enterome leverages its understanding of the gut microbiome–immune interaction to discover and develop small molecules, proteins and peptide therapeutics for cancer, autoimmune, inflammatory and metabolic diseases. Its pipeline includes cancer immunotherapies (EO2401, EO2463), EndoMimics biologics (EM101) for inflammatory diseases, and EB8018 (sibofimloc/TAK-018), an oral FimH blocker advancing in Crohn’s disease trials. EO2401 was expected to enter Phase 1/2 trials in glioblastoma and adrenal malignancies in mid-2020, while EO2463 is being prepared as a clinical candidate for B‑cell malignancies. EB8018 is partnered globally with Takeda, with Enterome retaining a significant profit share in the US. The company has operations in Paris and Boston and is led by CEO Pierre Belichard. Enterome recently closed a €46.3M financing and drew the first tranche from a previously agreed European Investment Bank loan facility to support clinical development. Enterome is a clinical-stage biotech pioneering microbiome-derived pharmaceuticals and diagnostics targeting inflammatory bowel diseases and cancer. Its lead programs are EB8018, an oral gut‑restricted FimH blocker for Crohn’s disease, and EO2315, an immuno‑oncology candidate derived from bacterial antigens. EB8018 completed a Phase 1 trial in 2017 showing safety and minimal blood absorption and is advancing to Phase 2; EO2315 has produced strong immune responses and tumor cell‑killing ex vivo and controlled tumor growth in vivo and is entering a Phase 1b study in glioblastoma. The company is also developing the next generation of its proprietary metagenomics drug discovery platform to expand therapeutic target discovery. Enterome has established partnerships with pharmaceutical companies (including Johnson & Johnson/Janssen, Takeda, Abbvie and Bristol‑Myers Squibb) and a 50/50 joint venture with Nestlé Health Science for microbiome diagnostics. The company was founded in 2012 in Paris. Enterome Bioscience SA, based in Paris and Boston, pioneers pharmaceuticals and diagnostics derived from the gut microbiome. Its lead therapeutic candidate is EB 8018, a novel small-molecule FimH antagonist licensed from Vertex that targets Adherent Invasive Escherichia coli (AIEC) proliferation. EB 8018 is being developed as a potential treatment for inflammatory bowel diseases and acts by preventing AIEC adhesion to the gut wall to help restore a dysbiotic microbiome. The company also develops microbiome-based diagnostics for IBD and other microbiome-related diseases and seeks partnerships with diagnostic and pharmaceutical companies. Enterome intends to advance therapeutic programs in immuno-oncology alongside its diagnostics and gut-focused therapies. The company will use the recent financing to support moving EB 8018 into first clinical studies in 2016. Enterome Bioscience develops disease management solutions and diagnostic products grounded in gut microbiome science. The company is building diagnostic tools to support patient stratification, personalized therapies and the clinical development of new drugs. Target indications include microbiome-related diseases such as inflammatory bowel diseases and metabolic diseases like diabetes and obesity. Enterome intends to use newly raised funds for R&D and business development activities. Founded in 2012 and led by CEO Pierre Belichard, the company is based in Paris, France. To date it has raised a total of €17.5m.

Participated · Series A · Apr 2025

Solu Therapeutics is a biotechnology company pioneering therapies that eliminate disease-driving cells across cancer, immunology, and other therapeutic areas using proprietary CyTAC and TicTAC platforms. Its lead candidate, STX-0712, is a CyTAC designed to target CCR2 and selectively eliminate CCR2-positive malignant monocytes, with an initial focus on CMML and other hematologic malignancies. The company has initiated a first-in-human, open-label, multicenter Phase 1 trial of STX-0712 with a two-part design: Part A dose escalation to determine the maximum tolerated dose and/or minimum effective dose in resistant/refractory CMML, and Part B to evaluate safety, tolerability, recommended Phase 2 dose, and preliminary antitumor activity. Solu presented preclinical ex vivo data at the 2024 ASH Annual Meeting showing robust activity of STX-0712 against CCR2-positive monocytes from CMML patient samples. Proceeds from the recent financing will be used to complete dose escalation and expansion of STX-0712, generate new development candidates including a first-in-class mast cell depletor for immunological diseases, advance additional discovery programs, and explore new applications for the CyTAC and TicTAC platforms. The company was cofounded by Longwood Fund and is based in Boston. Solu Therapeutics is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity using its proprietary CyTaC (Cytotoxicity Targeting Chimera) platform. CyTaC molecules, licensed from GSK, aim to unlock antibody-intractable cell surface targets and combine the potency of biologics with the broad target binding of small molecules. Characteristics of the platform include unlocking new tumor-associated antigens to eliminate cancer cells, depleting pathogenic immune cells, and extending the half-life of small-molecule antagonists and agonists. The company intends to use the financing to develop the proprietary CyTaC platform and associated drug candidates in-licensed from GSK. Under the license, GSK received equity in Solu and will receive milestones and royalties on products derived from the CyTaC platform. Solu is led by co-founder and CEO David Donabedian, Ph.D., and is based in Boston, MA.

Participated · Series B · Jan 2023

Immune-Onc Therapeutics is a private, clinical-stage cancer immunotherapy company developing novel myeloid checkpoint inhibitors targeting the LILRB family. Its lead clinical candidates are IO-108, an antagonist antibody targeting LILRB2 (ILT4) in Phase 1 for advanced solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (ILT3) in Phase 1 for AML, CMML and solid tumors. Additional pipeline assets include IO-106 (a LAIR1 antagonist), IO-312 (a bispecific targeting LILRB4) and multiple undisclosed programs. The company has collaborations and supply agreements with Regeneron and BeiGene to evaluate IO-108 and IO-202 in combination with anti-PD-1 therapies, and has received research grants from the NCI and CIRM. Headquartered in Palo Alto, California, Immune-Onc has also received strategic investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP) and Wuxi Biologics HealthCare Venture. Management highlighted ongoing clinical milestones including dose escalation and expansion cohorts, FDA Fast Track designation for IO-202 in relapsed or refractory AML, and plans to further characterize biomarkers and mechanisms of action. Immune-Onc Therapeutics is a clinical-stage cancer immunotherapy company focused on developing novel biotherapeutics that target immunosuppressive myeloid checkpoints, specifically the LILRB family. Its lead program, IO-202, is a first-in-class antibody against LILRB4 (ILT3) being developed for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors; preclinical data indicate it can activate T-cell killing and enhance tumor cell detection. IO-202 entered a Phase I trial in September 2020 for AML with monocytic differentiation and CMML and received FDA Orphan Drug Designation for AML in October 2020. The company’s IO-108, an antagonist antibody targeting LILRB2 (ILT4), is in the IND‑enabling stage with plans to submit an IND in mid‑2021; other preclinical assets include IO-106 (anti-LAIR1) and multiple undisclosed programs. Immune-Onc has invested in proprietary models, assays and tools to interrogate myeloid biology and maintains strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Financially, the company has raised over $110 million since beginning operations in 2016 and is advancing its pipeline toward additional clinical milestones using newly raised capital. Immune-Onc Therapeutics is focused on the discovery and development of novel biologic treatments that target the tumor microenvironment and immune suppressive pathways. The company aims to translate unique scientific insights into first-in-class biotherapeutics and has a pipeline built on collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Headquartered in Palo Alto, California, Immune-Onc is preparing to move from translational research into the clinic. To support that transition it received Series B funding of more than $33 million to advance its pipeline programs. The company recently appointed Dr. Adrian Jubb as Chief Medical Officer and Dr. An Song as Senior Vice President of Development Sciences to lead clinical, regulatory, and translational development efforts. Immune-Onc describes a leadership team with deep drug-development experience drawn from leading biotechnology and pharmaceutical organizations. Immune-Onc Therapeutics is a Palo Alto, CA-based biopharmaceutical company co-founded in 2016 by Charlene Liao, Ph.D., and Guo-Liang Yu, Ph.D. The company focuses on discovering and developing novel therapeutic antibodies for cancer treatment. It applies scientific insights and drug-development expertise to advance immuno-oncology products. Immune-Onc plans to use its new financing to support discovery and development activities for its antibody programs. In June 2016 it raised $7M in a Series A to provide initial funding to advance its pipeline.